For the quarter ending 2025-09-30, OKUR had -$13,043K decrease in cash & cash equivalents over the period. -$13,043K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -14,699 | -31,315 |
| Share-based compensation expense | 2,961 | 5,653 |
| Depreciation and amortization | 108 | 235 |
| Amortization of right-of-use asset - operating | 96 | 189 |
| Loss on disposal of property and equipment | -2 | - |
| Prepaid and other assets | 5 | -1,057 |
| Accounts payable, accrued and other liabilities | -1,364 | -2,876 |
| Lease liabilities | -136 | -262 |
| Other long-term liabilities | 0 | 40 |
| Net cash used in operating activities | -13,037 | -27,279 |
| Purchases of property and equipment | 6 | 31 |
| Net cash used in investing activities | -6 | -31 |
| Payment of issuance costs associated with the concurrent financing-Private Placement | 0 | 37 |
| Payment of reverse recapitalization transaction costs | 0 | 40 |
| Net cash (used in) provided by financing activities | 0 | -77 |
| Net decrease in cash and cash equivalents | -13,043 | -27,387 |
| Cash and cash equivalents at beginning of period | 110,761 | - |
| Cash and cash equivalents at end of period | 70,331 | - |
OnKure Therapeutics, Inc. (OKUR)
OnKure Therapeutics, Inc. (OKUR)